Traditionally, biologists have devoted their careers to studying individual biological entities of their own interest, partly due to lack of available data regarding that entity. Large, highthroughput data, too complex for conventional processing methods (i.e., "big data"), has accumulated in cancer biology, which is freely available in public data repositories. Such challenges urge biologists to inspect their biological entities of interest using novel approaches, firstly including repository data retrieval. Essentially, these revolutionary changes demand new interpretations of huge datasets at a systems-level, by so called "systems biology". One of the representative applications of systems biology is to generate a biological network from high-throughput big data, providing a global map of molecular events associated with specific phenotype changes. In this review, we introduce the repositories of cancer big data and cutting-edge systems biology tools for network generation, and improved identification of therapeutic targets. [BMB Reports 2017; 50(1): 12-19]
INTRODUCTION
Traditionally, researchers have focused their efforts on single biological phenomena (e.g., a single gene mutation) or a specific signaling pathway (1) . Now, the age of "omics" big data has brought about cutting-edge processing methods for interpreting biological mega data, which have now universally adopted. Based on such mega data (so-called "big data"), researchers aim to understand systems-level-based phenotype changes (1, 2) by assessing entire pathways/networks, and not just a single entity. Systems biology is defined as a framework (3) to enable systems-level understanding for generating new biological hypotheses, by computational modeling of massive high-throughput data.
Currently, systems biology has broadened its applications from basic science (including small RNAs) (4-6) toward translational medicine, including biomarker and therapeutic target identification (1-3, 7, 8) . Systems biology often begins from high-throughput experimental data. Due to mammoth data deposition, as well as data generation by various next-generation sequencing (NGS) techniques (9) , big data science has emerged, in particular, from the field of cancer genomics (10) . The most widely used repositories include The Cancer Genome Atlas (TCGA) Research Network (11) and the International Cancer Genome Consortium (ICGC) (12) . The development of applications for big data science (10) has been facilitated by systems biology frameworks to allow interpretation of systems-level tumorigenesis and molecular mechanisms.
Systems biology covers several diverse areas (13) : hypothesis generation and network construction (or inference), and network simulation (e.g., ordinary differential equations, boolean dynamics). In this review, we restrict our discussion to network generation, while also describing analysis tools and relating databases in the field of cancer.
A WORKFLOW OF SYSTEMS BIOLOGY
Systems biology has a straightforward workflow of components (13) , as shown in Fig. 1A . To understand systems-level biology, observations for all entries are necessary, and highthroughput data is merely a starting point. Computational modeling takes the high-throughput data and, in certain circumstances, prior knowledge (including pathways and gene sets) is selected, resulting in network inference and hypothesis generation (13) . Depending on whether computational modeling is used with or without prior knowledge, one may employ both data-driven network modeling and hybrid network modeling, respectively (14) . In both of them, computational modeling is a key component, due to its ability to deal with the complexity of interconnectivity among systems entries (13, 14) .
HIGH-THROUGHPUT DATA AND ITS REPOSITORIES
Currently, there are numerous types of high-throughput data (i.e., "omics"), including genomics, epigenomics, transcriptomics, The flow (represented by "edges") of genetic information from DNA to protein is aligned with the diverse data types. Public repositories corresponding to each data type are listed (further description in Table 1 ). (C) Network differences between correlationbased approaches and Bayesian networks approaches. The correlation (or mutual information) oriented tools, ARACNE (39) and WGCNA (36), do not report directions of edges in networks. Bayesian-driven networks naturally reveal directed edges among the network entries. In other words, the undirected network (in left of the grey-shaded triangular) having G1, G2, and G3 entries by ARACNE and WGCNA can be differentiated into directed networks (in the right of the grey-shaded triangular), using Bayesian networks tools (48-51).
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metabolomics, and proteomics (15) . As shown in Fig. 1B , the omics data types are aligned with the flow of genetic information in biology. Cancer genomics data in various types of cancers, including whole genome sequencing (WGS), whole exome sequencing (WES), and SNP array, has already been deposited in several public repositories including The Cancer Genome Atlas (TCGA) (11) , and International Cancer Genome Consortium (ICGC) (12, 16) (Fig. 1B) . Epigenomics in public databases, including the Encyclopedia of DNA Elements (ENCODE) (17) 1A is not restricted to one specific data type, and users should be prudent to inspect all the data types of their interest through multiple repositories, and not a single one. The brief information of the repositories is described in Table 1 . 
PRIOR KNOWLEDGE

COMPUTATIONAL MODELING AND ITS APPLICATION TO CANCER
Depending on prior knowledge usage, computational modeling, a key component in systems biology frameworks, can be divided into two modeling methods: hybrid method and data-driven method. The former incorporates prior knowledge in model development, while the latter infers networks or hypotheses directly from measurements, without prior knowledge. The tools described below are summarized in Table 2 . weighted adjacency matrix between gene pairs by calculating power adjacency function (41), resulting in connections among the gene entries. WGCNA has also been applied to diverse diseases, including cancer, for identifying therapeutic targets and tumorigenesis "driver" genes (42-44).
DATA-DRIVEN METHODS
Despite the great success of correlation-and mutual information-based approaches, these approaches often generate extensive links between network entries. Consequently, methods have now been introduced to reduce non-significant links. For example, sparse inverse covariance selection (SICS) (45, 46) infers a gene regulatory network from various data types by reducing non-significant links. The main function of SCIS is to identify a subset of network entries that consists of statistically significant or optimal pairwise correlations, based on the entire correlation (equivalent to covariance) matrix between all the entries. The benefit of subset identification is that it can provide statistically direct relations with smaller number of entries. SICS methods aim at maximizing or optimizing log-likelihood of pairwise correlations, assuming pairwise correlations as Gaussian graphical models (46, 47) or multivariate Gaussian models (45). Cancer Landscapes (cancerlandscapes.org) utilizes SICS, not only to provide multiple cancer network modules, but also to integrate multilevel omics data types into statistical network modules (45).
Unlike ARACNE and WGCNA, there are several approaches to generate directed networks (Fig. 1C) . Bayesian networks, another data-driven approach, utilizes a basic conditional independence (48-51). Bayesian networks is, by definition, that joint density probability of biological entries (e.g., genes) is the product of conditional probabilities of the entries in the omics data (38, 52). The definition naturally confers the ability to prune edges of the conditionally independent entries. Also, conditional dependency defines statistically casual relationships among gene entries, resulting in directed networks. The purpose of Bayesian networks is to identify the set of conditional probabilities that best describe measurements (e.g., gene expression) of biological entries in omics databases.
Banjo (users.cs.duke.edu/software) is another gene regulatory network generation tool that utilizes Bayesian network frameworks, resulting in directed networks (48). Banjo is applicable not only for single-state transcriptome data, but also for time-series data. Banjo (Bayesian network interference with Java objects) uses the multiple types of heuristic network searching to find candidate networks (equivalently, graphs), such as simulated annealing with a greedy algorithm (53), and genetic algorithm (48). The conditional probability densities of each network are estimated, and the network scores (e.g., Bayesian Information Criterion (BIC), Bayesian Dirichlet equivalence (BDe)) are then calculated. Finally, Banjo reports the network with the best score, based on its best directed edges between its entries. Banjo has also been applied to leukemia, revealing miRNA-relating network hierarchy by http://bmbreports.org merging gene expression, gene regulatory networks, and copy number alterations (54).
One obstacle to all these prediction methods is that there are no "gold standards" for data-driven network generation tools. Consequently, the performance of the data-driven methods depends on data types, model parameter settings, network size, and network topology (55).
HYBRID METHODS
In hybrid methods, models are generated to analyze highthroughput data via prior knowledge (e.g., gene sets, pathways) (56), resulting in network inference. Traditionally to date, hybrid methods use pathways as prior knowledge. Recently, gene sets have been recognized as another prior knowledge source for inferring networks that consist of entries and their mutual interactions.
Another tool, EDDY (evaluation of dependency differentiality) (28) considers two conditions, and applies Bayesian networks framework to all the gene sets. EDDY selects the best network structure for each gene set, by using Jensen-Shannon (JS) divergences and permutation tests from all possible network structures. The tool then calculates the two probability density distributions of a network structure for the two conditions. Subsequently, EDDY calculates JS divergence for the two distributions of the network structure, measuring JS divergence as the difference of the two distributions. The significance of JS divergence is measured by the permutation test, identifying the best network structure having statistically significant JS divergence. The output is a network that consists of the entries (of the gene set) and their interactions between the entries. The tool was recently applied to glioblastoma multiforme (GBM), resulting in the successful identification of specific molecular subtypes of glioblastoma (28).
Prior pathway information with omics data has been incorporated into statistical frameworks for the past ten years (7, 8, 57) , successfully generating network structures. In this approach, the challenge to build the statistical framework is developing and defining a statistic reflecting pathway topology. Pathway topology indicates interaction types (e.g., activation, inhibition, modification) as well as order (e.g., upstream, downstream) of biological entries. Another tool, SPIA (signaling pathway impact analysis) (58) (bioconductor.org/packages/ release/bioc/html/SPIA.html), utilizes the KEGG pathway database as prior knowledge. Instead of utilizing the individual signaling molecules (in KEGG pathways), SPIA aligns the consecutive KEGG signaling "flows" with omics data. Additionally, SPIA now considers two types of a flow between two adjacent signaling molecules: activation and inhibition. SPIA quantitatively measures influence (i.e., perturbation statistic in a given pathway) on signal cascading flows by using omics data between two experimental groups. For any given pathway, SPIA obtains P values for the perturbation statistic by using permutation tests. SPIA also reconstructs statistically significant pathways in a network. Recently, SPIA was applied to aggressive prostate cancer, discovering that the disease shares a pathway network with small cell lung cancer (59).
We also developed pathway topology-driven hybrid methods (7, 8) , specifically for network generation, including PATHOME (7). These two methods also input the KEGG database (29) as prior knowledge for network generation. The earlier algorithm (8) (henceforth, pre-PATHOME) identified subsets of all KEGG pathways by utilizing permutation-oriented statistical tests, based on a whole transcriptome. Since graphical structures of the KEGG pathways are too complex, we decomposed to all the possible paths (∼130 million, equivalently, subpathways) by traversing the graph structures.
In pre-PATHOME, each path consists of biological entries and their mutual interactions between adjacent two entries, either activation or inhibition. Given a subpathway, we devised a statistic to consider interactions (equivalently, edges) of two adjacent entries, as well as orders of biological entities (8) . We assumed the first order Markov property (denoted as Fedge in (8)) where the fold-changes of the entities were regarded as observations. Subsequently, we performed permutationbased statistical tests for the product of Fedge and two additional statistics in each path. The statistically significant paths were collected and visualized. The pre-PATHOME was applied to an early onset colorectal cancer (CRC) dataset (60) , revealing the pathways of epithelial-to-mesenchymal transition and immunosuppression even in normal adjacent cells of the CRC patients (8) . The pre-PATHOME (8) was also deployed to identify trastuzumab-resistance pathways relating to networks in HER2(＋) breast cancer (61), revealing five biomarker candidates associated with trastuzumab non-responsiveness (ATF4, CHEK2, ENAH, ICOSLG, and RAD51).
Our group recently developed another hybrid method, PATHOME, (7). The pre-PATHOME (8) assumed that all interactions in a subpathway are dependent on their upstream entities (the so called, first order Markov property). PATHOME assumes that all edges in a subpathway are independent, adopting a two-stage strategy in our statistical framework (7) . In the first stage, out of 130 million KEGG subpathways, PATHOME selects those with their edges aligned with correlations. In the second stage, we test the selected subpathways under the null hypothesis, that no differential correlation patterns between two groups are observed. Despite the independence assumption among edges, PATHOME showed better agreement with a cancer signaling reference set (62) , when compared to other gene set analysis tools (e.g., DAVID (63) , and GSEA (25)). PATHOME has also been applied for delineating druggable target candidates, as well as molecular mechanisms, in both gastric and breast cancers (7, 64, 65) . Recently, PATHOME was applied to gastric cancer (GC) transcriptome datasets, suggesting a HNF4/WNT5A axis to be a new druggable signaling, as well as having a clinical relevance in diffuse type GC (64, 65) . 
